Cyclo Ev To Free Cash Flow vs Price Cash Flow Ratio Analysis

CYTHW Stock

USD 0.14 0.00 0.00%

Cyclo Therapeutics financial indicator trend analysis is way more than just evaluating Cyclo Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Cyclo Therapeutics is a good investment. Please check the relationship between Cyclo Therapeutics Ev To Free Cash Flow and its Price Cash Flow Ratio accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cyclo Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.

For more information on how to buy Cyclo Stock please use our How to Invest in Cyclo Therapeutics guide.

Ev To Free Cash Flow vs Price Cash Flow Ratio

Ev To Free Cash Flow vs Price Cash Flow Ratio Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Cyclo Therapeutics Ev To Free Cash Flow account and Price Cash Flow Ratio. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between Cyclo Therapeutics' Ev To Free Cash Flow and Price Cash Flow Ratio is -0.31. Overlapping area represents the amount of variation of Ev To Free Cash Flow that can explain the historical movement of Price Cash Flow Ratio in the same time period over historical financial statements of Cyclo Therapeutics, assuming nothing else is changed. The correlation between historical values of Cyclo Therapeutics' Ev To Free Cash Flow and Price Cash Flow Ratio is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Ev To Free Cash Flow of Cyclo Therapeutics are associated (or correlated) with its Price Cash Flow Ratio. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Price Cash Flow Ratio has no effect on the direction of Ev To Free Cash Flow i.e., Cyclo Therapeutics' Ev To Free Cash Flow and Price Cash Flow Ratio go up and down completely randomly.

Correlation Coefficient

-0.31

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Ev To Free Cash Flow

A valuation metric comparing the company's enterprise value to its free cash flow, used to evaluate whether a company is undervalued or overvalued.

Price Cash Flow Ratio

Most indicators from Cyclo Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Cyclo Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cyclo Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.

For more information on how to buy Cyclo Stock please use our How to Invest in Cyclo Therapeutics guide.At this time, Cyclo Therapeutics' Issuance Of Capital Stock is fairly stable compared to the past year. Sales General And Administrative To Revenue is likely to climb to 5.52 in 2024, whereas Enterprise Value Over EBITDA is likely to drop (0.93) in 2024.

	2021	2022	2023	2024 (projected)
Total Operating Expenses	15.7M	16.8M	17.6M	18.5M
Cost Of Revenue	156.1K	138.9K	3.5M	3.7M

Total Operating Expenses Cost Of Revenue

Cyclo Therapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock	Common Stock Total Equity	Property Plant And Equipment Gross	Other Current Liab
Total Assets		0.15	0.74	0.85	-0.22	-0.96	-0.71	0.81	0.98	-0.28	-0.35	0.98	0.68	0.64	-0.23	-0.16	0.53	0.79	0.73	0.99	0.4	-0.28	-0.42	-0.51	-0.18	0.38
Short Long Term Debt Total	0.15		0.41	-0.15	0.61	0.11	-0.39	0.14	-0.03	0.57	0.31	-0.03	-0.32	0.58	0.41	-0.14	0.45	0.37	0.47	0.04	0.76	-0.21	-0.37	-0.49	0.65	-0.71
Total Current Liabilities	0.74	0.41		0.29	-0.27	-0.64	-0.95	0.94	0.68	-0.34	-0.48	0.68	0.25	0.94	-0.07	-0.2	0.74	0.95	0.99	0.75	0.79	-0.23	-0.18	-0.37	-0.23	0.22
Total Stockholder Equity	0.85	-0.15	0.29		-0.15	-0.89	-0.3	0.45	0.88	-0.19	-0.19	0.88	0.79	0.18	-0.26	-0.04	0.2	0.4	0.28	0.84	-0.04	-0.23	-0.43	-0.41	-0.12	0.43
Property Plant And Equipment Net	-0.22	0.61	-0.27	-0.15		0.42	0.39	-0.49	-0.35	0.99	0.73	-0.35	-0.35	-0.17	0.03	0.12	-0.35	-0.38	-0.22	-0.36	0.05	-0.12	-0.09	-0.08	1.0	-0.82
Net Debt	-0.96	0.11	-0.64	-0.89	0.42		0.63	-0.79	-0.99	0.47	0.46	-0.99	-0.74	-0.5	0.28	0.16	-0.45	-0.71	-0.62	-0.98	-0.22	0.2	0.37	0.42	0.39	-0.58
Retained Earnings	-0.71	-0.39	-0.95	-0.3	0.39	0.63		-0.91	-0.66	0.46	0.56	-0.66	-0.3	-0.95	-0.17	0.23	-0.9	-0.99	-0.94	-0.74	-0.82	0.24	0.29	0.45	0.34	-0.27
Accounts Payable	0.81	0.14	0.94	0.45	-0.49	-0.79	-0.91		0.8	-0.55	-0.6	0.8	0.44	0.81	-0.13	-0.26	0.7	0.93	0.93	0.85	0.58	-0.24	-0.13	-0.28	-0.45	0.48
Cash	0.98	-0.03	0.68	0.88	-0.35	-0.99	-0.66	0.8		-0.4	-0.42	1.0	0.71	0.55	-0.29	-0.17	0.46	0.74	0.67	0.99	0.28	-0.22	-0.39	-0.46	-0.32	0.51
Non Current Assets Total	-0.28	0.57	-0.34	-0.19	0.99	0.47	0.46	-0.55	-0.4		0.8	-0.4	-0.36	-0.24	0.03	0.12	-0.41	-0.45	-0.28	-0.42	-0.03	-0.15	-0.04	-0.02	0.98	-0.8
Non Currrent Assets Other	-0.35	0.31	-0.48	-0.19	0.73	0.46	0.56	-0.6	-0.42	0.8		-0.42	-0.25	-0.4	-0.01	0.02	-0.49	-0.55	-0.42	-0.46	-0.28	-0.19	0.03	0.08	0.71	-0.53
Cash And Short Term Investments	0.98	-0.03	0.68	0.88	-0.35	-0.99	-0.66	0.8	1.0	-0.4	-0.42		0.71	0.55	-0.29	-0.17	0.46	0.74	0.67	0.99	0.28	-0.22	-0.39	-0.46	-0.32	0.51
Net Receivables	0.68	-0.32	0.25	0.79	-0.35	-0.74	-0.3	0.44	0.71	-0.36	-0.25	0.71		0.18	-0.25	-0.07	0.22	0.37	0.23	0.7	-0.14	-0.25	-0.07	-0.06	-0.32	0.58
Common Stock Shares Outstanding	0.64	0.58	0.94	0.18	-0.17	-0.5	-0.95	0.81	0.55	-0.24	-0.4	0.55	0.18		0.1	-0.21	0.81	0.94	0.95	0.64	0.9	-0.18	-0.3	-0.49	-0.13	0.03
Non Current Liabilities Total	-0.23	0.41	-0.07	-0.26	0.03	0.28	-0.17	-0.13	-0.29	0.03	-0.01	-0.29	-0.25	0.1		-0.19	0.56	0.11	-0.06	-0.22	0.34	-0.06	-0.35	-0.29	0.05	-0.31
Inventory	-0.16	-0.14	-0.2	-0.04	0.12	0.16	0.23	-0.26	-0.17	0.12	0.02	-0.17	-0.07	-0.21	-0.19		-0.26	-0.22	-0.27	-0.17	-0.02	-0.43	0.49	0.49	0.12	0.1
Other Current Assets	0.53	0.45	0.74	0.2	-0.35	-0.45	-0.9	0.7	0.46	-0.41	-0.49	0.46	0.22	0.81	0.56	-0.26		0.87	0.73	0.56	0.8	-0.18	-0.41	-0.5	-0.3	0.11
Other Stockholder Equity	0.79	0.37	0.95	0.4	-0.38	-0.71	-0.99	0.93	0.74	-0.45	-0.55	0.74	0.37	0.94	0.11	-0.22	0.87		0.94	0.81	0.79	-0.25	-0.33	-0.48	-0.33	0.29
Total Liab	0.73	0.47	0.99	0.28	-0.22	-0.62	-0.94	0.93	0.67	-0.28	-0.42	0.67	0.23	0.95	-0.06	-0.27	0.73	0.94		0.73	0.79	-0.23	-0.21	-0.4	-0.17	0.16
Total Current Assets	0.99	0.04	0.75	0.84	-0.36	-0.98	-0.74	0.85	0.99	-0.42	-0.46	0.99	0.7	0.64	-0.22	-0.17	0.56	0.81	0.73		0.38	-0.24	-0.39	-0.48	-0.33	0.49
Short Term Debt	0.4	0.76	0.79	-0.04	0.05	-0.22	-0.82	0.58	0.28	-0.03	-0.28	0.28	-0.14	0.9	0.34	-0.02	0.8	0.79	0.79	0.38		-0.18	-0.29	-0.46	0.09	-0.26
Intangible Assets	-0.28	-0.21	-0.23	-0.23	-0.12	0.2	0.24	-0.24	-0.22	-0.15	-0.19	-0.22	-0.25	-0.18	-0.06	-0.43	-0.18	-0.25	-0.23	-0.24	-0.18		-0.33	-0.28	-0.15	-0.28
Common Stock	-0.42	-0.37	-0.18	-0.43	-0.09	0.37	0.29	-0.13	-0.39	-0.04	0.03	-0.39	-0.07	-0.3	-0.35	0.49	-0.41	-0.33	-0.21	-0.39	-0.29	-0.33		0.97	-0.1	0.27
Common Stock Total Equity	-0.51	-0.49	-0.37	-0.41	-0.08	0.42	0.45	-0.28	-0.46	-0.02	0.08	-0.46	-0.06	-0.49	-0.29	0.49	-0.5	-0.48	-0.4	-0.48	-0.46	-0.28	0.97		-0.1	0.27
Property Plant And Equipment Gross	-0.18	0.65	-0.23	-0.12	1.0	0.39	0.34	-0.45	-0.32	0.98	0.71	-0.32	-0.32	-0.13	0.05	0.12	-0.3	-0.33	-0.17	-0.33	0.09	-0.15	-0.1	-0.1		-0.81
Other Current Liab	0.38	-0.71	0.22	0.43	-0.82	-0.58	-0.27	0.48	0.51	-0.8	-0.53	0.51	0.58	0.03	-0.31	0.1	0.11	0.29	0.16	0.49	-0.26	-0.28	0.27	0.27	-0.81

Click cells to compare fundamentals

Cyclo Therapeutics Account Relationship Matchups

Cyclo Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	4.1M	14.2M	19.5M	4.2M	13.2M	13.9M
Total Current Liabilities	3.1M	3.7M	3.8M	3.5M	8.5M	8.9M
Total Stockholder Equity	936.0K	10.5M	15.7M	734.5K	4.8M	2.6M
Property Plant And Equipment Net	64.6K	87.9K	77.2K	56.7K	929.3K	505.7K
Net Debt	(2.7M)	(12.7M)	(16.4M)	(1.5M)	(8.2M)	(7.8M)
Retained Earnings	(25.1M)	(34.1M)	(48.3M)	(63.8M)	(83.9M)	(79.7M)
Accounts Payable	3.1M	3.5M	3.7M	2.2M	4.9M	5.1M
Cash	2.8M	12.8M	16.6M	1.5M	9.2M	9.7M
Non Current Assets Total	155.2K	137.7K	84.5K	56.7K	929.3K	694.6K
Non Currrent Assets Other	90.6K	49.8K	7.3K	(56.7K)	38.3K	36.4K
Cash And Short Term Investments	2.8M	12.8M	16.6M	1.5M	9.2M	9.7M
Net Receivables	182.5K	111.8K	539.1K	55.0K	122.4K	105.2K
Common Stock Shares Outstanding	1.1M	1.6M	6.4M	8.4M	16.3M	17.1M
Liabilities And Stockholders Equity	4.1M	14.2M	19.5M	4.2M	13.2M	13.9M
Non Current Liabilities Total	36.1K	62.9K	18.0K	3.5M	22.5K	21.4K
Inventory	242.6K	237.9K	227.4K	254.5K	254.4K	250.7K
Other Current Assets	749.2K	854.4K	2.1M	4.6M	2.7M	2.8M
Other Stockholder Equity	26.0M	44.5M	64.0M	64.5M	88.6M	93.0M
Total Liab	3.2M	3.7M	3.8M	3.5M	8.5M	8.9M
Total Current Assets	4.0M	14.1M	19.4M	4.2M	12.3M	12.9M
Common Stock	12.2K	477.0	841.0	849.0	2.9K	3.7K
Common Stock Total Equity	9.1K	12.2K	477.0	849.0	976.35	927.53
Property Plant And Equipment Gross	64.6K	87.9K	159.3K	158.2K	1.1M	533.5K
Capital Surpluse	18.7M	26.0M	44.5M	64.5M	74.2M	77.9M
Property Plant Equipment	18.6K	64.6K	87.9K	55.2K	63.5K	51.7K
Net Invested Capital	936.0K	10.6M	15.8M	734.5K	4.8M	5.5M
Net Working Capital	816.9K	10.4M	15.6M	677.9K	3.9M	5.2M
Capital Stock	12.2K	477.0	841.0	849.0	2.9K	3.5K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for Cyclo Stock Analysis

When running Cyclo Therapeutics' price analysis, check to measure Cyclo Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cyclo Therapeutics is operating at the current time. Most of Cyclo Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cyclo Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cyclo Therapeutics' price. Additionally, you may evaluate how the addition of Cyclo Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Cyclo Ev To Free Cash Flow vs Price Cash Flow Ratio Analysis

Ev To Free Cash Flow vs Price Cash Flow Ratio

Ev To Free Cash Flow vs Price Cash Flow Ratio Correlation Analysis

Correlation Coefficient

Ev To Free Cash Flow

Price Cash Flow Ratio

Cyclo Therapeutics fundamental ratios Correlations

Cyclo Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Cyclo Therapeutics fundamental ratios Accounts

Also Currently Popular

Additional Tools for Cyclo Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Cash And Short Term Investments	+ 1.0	Cash
Total Current Assets	+ 0.99	Total Assets
Total Liab	+ 0.99	Total Current Liabilities
Non Current Assets Total	+ 0.99	Property Plant And Equipment Net
Total Current Assets	+ 0.99	Cash

Other Stockholder Equity	- 0.99	Retained Earnings
Cash And Short Term Investments	- 0.99	Net Debt
Cash	- 0.99	Net Debt
Total Current Assets	- 0.98	Net Debt
Net Debt	- 0.96	Total Assets
Common Stock Shares Outstanding	- 0.95	Retained Earnings